Bassem Refaat1, Tariq Helal Ashour1, Adel Galal El-Shemi2. 1. Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University Al-Abdeyah, Makkah, PO Box 7607, KSA. 2. Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University Al-Abdeyah, Makkah, PO Box 7607, KSA ; Department of Pharmacology, Faculty of Medicine, Assiut University Egypt.
Abstract
OBJECTIVES: To measure the effect of vitamin D3 (VitD) supplementation on erythrocyte indices, serum and kidney erythropoietin (EPO) in normal rats treated with Pegylated interferon-α (Peg-INF-α) and ribavirin (RBV). MATERIALS AND METHODS: Eighty male Wistar rats were divided equally into 8 groups. 'Control'; 'P': only received Peg-INF-α; 'PD': Peg-INF-α/VitD; 'PR': Peg-INF-α/RBV; 'PRD': Peg-INF-α/RBV/VitD; 'R': only received RBV; 'RD': RBV/VitD and 'VitD': only received vitamin D3. Peg-INF-α-2a was injected subcutaneously (6 µg/rat/week) for 4 weeks. RBV (4 mg/rat/day) and VitD (500 IU/rat/day) were given orally for 5 weeks. Blood samples were collected to measure erythrocyte indices and serum 25(OH) vitamin D. EPO was measured in serum samples and kidney specimens by ELISA. RESULTS: Peg-INF-α alone did not affect the RBCs count, haemoglobin, serum and kidney EPO compared to control (P > 0.05). RBV significantly decreased (P < 0.05) the erythrocyte count, haemoglobin and EPO levels in kidney and serum, either individually (R group) or combined with Peg-INF-α (PR group), compared to 'Control' and 'P' groups. VitD prevented the development of anaemia and significantly increased the concentrations of EPO at serum and kidney levels in the 'RD' and 'PRD' groups compared to 'R' and 'PR' groups. There was a significant positive correlation between blood levels of VitD with serum and kidney EPO, Red cell count and haemoglobin concentrations. CONCLUSION: VitD could have a potential beneficial role in the prevention of ribavirin-induced anaemia by promoting endogenous EPO. Further studies are needed to explore the role of vitamin D in the prevention of ribavirin associated anaemia.
OBJECTIVES: To measure the effect of vitamin D3 (VitD) supplementation on erythrocyte indices, serum and kidney erythropoietin (EPO) in normal rats treated with Pegylated interferon-α (Peg-INF-α) and ribavirin (RBV). MATERIALS AND METHODS: Eighty male Wistar rats were divided equally into 8 groups. 'Control'; 'P': only received Peg-INF-α; 'PD': Peg-INF-α/VitD; 'PR': Peg-INF-α/RBV; 'PRD': Peg-INF-α/RBV/VitD; 'R': only received RBV; 'RD': RBV/VitD and 'VitD': only received vitamin D3. Peg-INF-α-2a was injected subcutaneously (6 µg/rat/week) for 4 weeks. RBV (4 mg/rat/day) and VitD (500 IU/rat/day) were given orally for 5 weeks. Blood samples were collected to measure erythrocyte indices and serum 25(OH) vitamin D. EPO was measured in serum samples and kidney specimens by ELISA. RESULTS:Peg-INF-α alone did not affect the RBCs count, haemoglobin, serum and kidney EPO compared to control (P > 0.05). RBV significantly decreased (P < 0.05) the erythrocyte count, haemoglobin and EPO levels in kidney and serum, either individually (R group) or combined with Peg-INF-α (PR group), compared to 'Control' and 'P' groups. VitD prevented the development of anaemia and significantly increased the concentrations of EPO at serum and kidney levels in the 'RD' and 'PRD' groups compared to 'R' and 'PR' groups. There was a significant positive correlation between blood levels of VitD with serum and kidney EPO, Red cell count and haemoglobin concentrations. CONCLUSION: VitD could have a potential beneficial role in the prevention of ribavirin-induced anaemia by promoting endogenous EPO. Further studies are needed to explore the role of vitamin D in the prevention of ribavirin associated anaemia.
Entities:
Keywords:
Anaemia; erythropoietin hormone; pegylated interferon-α; ribavirin and vitamin D
Authors: John G McHutchison; Michael Manns; Keyur Patel; Thierry Poynard; Karen L Lindsay; Christian Trepo; Jules Dienstag; William M Lee; Carmen Mak; Jean-Jacques Garaud; Janice K Albrecht Journal: Gastroenterology Date: 2002-10 Impact factor: 22.682
Authors: John G McHutchison; Michael P Manns; Robert S Brown; K Rajender Reddy; Mitchell L Shiffman; John B Wong Journal: Am J Gastroenterol Date: 2007-04 Impact factor: 10.864
Authors: Noemi Hernández-Alvarez; Juan Manuel Pascasio Acevedo; Enrique Quintero; Inmaculada Fernández Vázquez; María García-Eliz; Juan de la Revilla Negro; Javier Crespo García; Manuel Hernández-Guerra Journal: BMJ Open Gastroenterol Date: 2017-03-04
Authors: Camille G Apple; Elizabeth S Miller; Kolenkode B Kannan; Julie A Stortz; Michael Cox; Tyler J Loftus; Hari K Parvataneni; Matthew Patrick; Jennifer E Hagen; Scott Brakenridge; Philip A Efron; Alicia M Mohr Journal: J Trauma Acute Care Surg Date: 2020-12 Impact factor: 3.697
Authors: Sami A Gabr; Ahmad H Alghadir; Ahmed A Allam; Jamaan Ajarem; Ghada Al-Basher; Mostafa A Abdel-Maksoud; Ayman A Ghfar; Alaa Aboud Journal: Clin Interv Aging Date: 2016-05-04 Impact factor: 4.458
Authors: Betty Tyler; Nicolas Skuli; Joshua Casaos; Sakibul Huq; Tarik Lott; Raphael Felder; John Choi; Noah Gorelick; Michael Peters; Yuanxuan Xia; Russell Maxwell; Tianna Zhao; Chenchen Ji; Thomas Simon; Julie Sesen; Sarah J Scotland; Richard E Kast; Jeffrey Rubens; Eric Raabe; Charles G Eberhart; Eric M Jackson; Henry Brem Journal: Oncotarget Date: 2018-01-03